Engineered immune cells tested as new weapon against Tough-to-Treat blood cancer
NCT ID NCT03672318
Summary
This is an early-stage study testing the safety of a new cell therapy for adults with multiple myeloma that has come back or stopped responding to standard treatments. Doctors take a patient's own immune cells (T-cells), modify them in a lab to better recognize and attack cancer cells, and then infuse them back into the patient. The main goal is to find a safe dose and understand the side effects of this experimental treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.